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Background: Clinically identifiable potentially malignant disorders (PMD) 
precede oral squamous cell carcinoma development. Oral lichenoid lesions 
(OLL) and proliferative verrucous leukoplakia (PVL) are specific precursor 
lesions believed to exhibit both treatment resistance and a high risk of 
malignant transformation (MT).   
Methods: A retrospective review of 590 PMD patients treated in Northern 
England by CO2 laser surgery between 1996 and 2014 was carried out. 
Lesions exhibiting lichenoid or proliferative verrucous features were identified 
from the patient database and their clinico-pathological features and 
outcome post-treatment determined at the study census date of 31 
December 2014. 
Results: 198 patients were identified: 118 OLL and 80 PVL, most frequently 
leukoplakia at ventro-lateral tongue and floor of mouth sites, equally 
distributed between males and females. Most exhibited dysplasia on incision 
biopsy (72% OLL; 85% PVL) and were treated by laser excision rather than 
ablation (88.1% OLL; 86.25% PVL). OLL were more common in younger 
patients (OLL 57.1yrs; PVL 62.25yrs; p=0.008) and more likely than PVL to 
present as erythroleukoplakia (OLL 15.3%; PVL 2.5%; p = 0.003). Whilst no 
significant difference was seen between OLL and PVL achieving disease 
free status (69.5% and 65%, respectively; p = 0.55), this was less than the 
overall PMD cohort (74.2%). MT was identified in 2 OLL (1.7%) and 2 PVL 
(2.5%) during follow-up.   
Conclusion: One-third of PMD cases showed features of OLL or PVL, 
probably representing a disease presentation continuum. Post-treatment 











Potentially malignant disorders (PMD) are clinically discernible oral diseases, 
most frequently localised mucosal disorders such as leukoplakia, 
erythroplakia and erythroleukoplakia, but also widespread abnormalities such 
as proliferative verrucous leukoplakia (PVL) or controversially oral lichenoid 
lesions (OLL), that precede in an unpredictable manner invasive oral 
squamous cell carcinoma (OSCC) development1,2. Contemporary PMD 
management is based upon initial incision biopsy to provide histological 
assessment and severity grading of underlying tissue disorganisation and 
dysmaturation changes characteristic of epithelial dysplasia, followed by 
targeted surgical excision for definitive diagnosis and treatment of lesions 
deemed ‘high-risk’ for malignant transformation (MT)3,4,5.  
Whilst systematic review has estimated an overall 12% MT risk over a mean 
period of 4.3 years6, clinico-pathological features associated with highest 
cancer risk include appearance of erythroplakia, erythroleukoplakia or PVL, 
mucosa exhibiting severe dysplastic change and origin on ventro-lateral 
tongue and floor of mouth sites3-6. In addition, in relation to OLL we have 
demonstrated persistence of disease post-treatment with poor long-term 
outcome, including an increased MT risk, often in the absence of 
recognisable dysplasia3,7,8. Whilst strict definition remains elusive, OLL are 
generally characterised histopathologically by the presence of lichenoid 
inflammation (LI), a band-like lymphohistiocytic infiltrate subjacent to 
hyperplastic or dysplastic epithelium; the latter finding is sometimes termed 
‘lichenoid dysplasia’9,10,11. However, multiple white hyperkeratotic lesions 
with a verrucous epithelial hyperkeratosis and ‘interface mucositis’ are also 
features of PVL and, by mimicking OLL, contribute to diagnostic confusion9. 
Long-term patient follow-up data are required to improve our understanding 
of the natural history of these disorders and to try to resolve the conundrum 
surrounding both diagnosis and management3.  
In a series of recent papers, we have defined and characterised clinical 





interventional CO2 laser treatment, primarily excision surgery but also 
ablation for small or less dysplastic lesions especially at gingiva and alveolar 
sites3,5,12. Post-treatment, 438 patients from this cohort (74.2%) were disease 
free (DF), 53 had persistent PMD disease and 99 (16.8%) exhibited either 
unexpected OSCC on excision (71 or 12%) or developed SCC subsequently 
(28 or 4.8%) during a mean 7.3 year follow-up period3,5,12.  
The specific purpose of this paper was to revisit this 590 PMD cohort and 
determine the prevalence of OLL and PVL in the population and to 
distinguish clinico-pathological features and post-treatment outcome data 




Caldicott Approval previously obtained from Newcastle University / 
Newcastle upon Tyne Hospitals NHS Foundation Trust facilitated 
anonymized, retrospective data collection from medical records, operating 
books and original pathology reports from PMD patients treated by laser in 
Maxillofacial Surgery between August 1996 and December 2014. Inclusion 
criteria for this review required new patients with single-site PMD disease 
and a histopathological diagnosis of LI or PVL. Detailed demographic and 
clinico-pathological data included: patient age and sex, lesion appearance 
and site, definitive histopathology diagnosis, treatment intervention (laser 
excision or ablation), and clinical outcome recorded at original study census 
date of 31 December 2014.  
All biopsies and CO2 laser surgeries were carried out by the first author 
(PJT), or colleagues working under direct supervision, to established 
guidelines and within 6 to 12 weeks of initial presentation to prevent disease 
progression3. Formalin-fixed tissue specimens were assessed via 
standardized histopathology examination by oral pathologists at the Royal 
Victoria Infirmary using agreed diagnostic criteria, peer review and 





used and dysplasia classified as mild, moderate or severe, with diagnoses of 
hyperkeratosis (HK), LI, and PVL made as appropriate. Clinical outcomes 
were listed as DF, further PMD disease or MT.   
Statistical Analyses 
Descriptive Statistics were used to summarise patient demography, clinico-
pathological features, clinical outcome and follow-up data. Pearson’s Chi-
squared tests (P values computed using Monte Carlo simulation with 2000 
replications) and logistic regression were used to assess possible 
associations between clinico-pathological features and post-treatment 
outcomes; the latter was classified for analysis as DF or further disease 
(including persistent PMD and MT). All statistical analyses were carried out 




Overall, 198 out of 590 patients (33.6%) received a histopathological 
diagnosis of either OLL (118 or 20%) or PVL (80 or 13.6%). Whilst the 
numbers of OLL diagnoses were reasonably consistent throughout the 18-
year period, PVL was more frequently identified during the later years of the 
study; 68 PVL cases (85%) being diagnosed between 2010 and 2014.  
Oral Lichenoid Lesions  
Table 1 lists the clinico-pathological details and treatment outcomes for 118 
OLL patients: 58 males and 60 females (age range 24-84yrs; mean 57.1yrs). 
In 99 cases (83.9%), lesions presented as leukoplakia with 19 
erythroleukoplakias (16.1%).  66 lesions (55.9%) arose at ventro-lateral 
tongue and floor of mouth sites, 30 (25.4%) on buccal or labial commissure 
mucosa, 16 (13.6%) on gingiva and alveolus, with other sites less frequently 
involved (6 cases or 5.1%). Histopathological diagnoses confirmed that 85 
lesions (72%) showed varying degrees of dysplasia upon incision biopsy (40 





and LI only. Whilst 104 lesions (88.1%) were excised by CO2 laser, 14 
(11.9%) underwent ablative treatment. 82 patients (69.5%) were documented 
disease free at census, whilst 36 (30.5%) developed further disease; 2 of the 
latter cases (1.7%) subsequently underwent MT. 
Proliferative Verrucous Leukoplakia  
Table 2 summarises the clinico-pathological data and disease outcome 
status for 80 patients exhibiting PVL: 41 males and 39 females (age range 
25-94yrs; mean 62.3yrs). Clinically, 78 lesions (97.5%) were leukoplakias 
with only 2 (2.5%) presenting as erythroleukoplakia. Ventro-lateral tongue 
and floor of mouth sites accounted for 31 lesions (38.7%), with buccal or 
labial commissure 21 (26.3%) and gingiva and alveolus 11 (13.7%); tongue 
dorsum, palate, fauces and labial mucosa sites accounted for a further 17 
(21.3%). Histopathological diagnoses showed that 68 lesions (85%) 
exhibited varying degrees of dysplasia (45 mild, 18 moderate and 5 severe), 
with 12 (15%) reported as PVL only. 69 lesions (86.3%) were excised by 
laser and 11 (13.7%) ablated. 52 patients (65%) were DF at time of census, 
with 28 (35%) developing further disease; 2 of these (2.5%) underwent MT. 
Diagnostic Discrepancy 
In 10 patients, 3 of which are highlighted in Table 1 and 7 in Table 2, 
histopathological diagnoses of LI and PVL were both ascribed. In 7 cases 
this was a ‘same-site’ discrepancy between initial incision and subsequent 
excision biopsy diagnoses whilst in another 3, further ‘new-site’ disease 
developed and was diagnosed as PVL or LI in a patient previously 
categorized by the alternate diagnosis. 
Statistical Analyses 
In terms of significant differences, OLL were usually seen in younger patients 
(logistic regression: wald χ2 = 7.09; p=0.008) and more likely than PVL to 
present as erythroplakia or erythroleukoplakia (Chi-squared test: χ2 = 9.303; 
p = 0.003). Whilst OLL presented most frequently on ventro-lateral tongue 
and floor of mouth mucosa, PVL was more evenly distributed amongst all 





OLL (Chi-squared test: χ2 = 16.018; p = 0.013). Table 3 summarizes 
statistical analyses of OLL and PVL clinico-pathological features that might 
influence clinical outcome status (DF or further disease) post-treatment. No 
significant influences were seen for patient age and sex, nor did the severity 
of dysplasia or the distinction between OLL and PVL affect outcome. On the 
other hand, both lesion appearance and site of origin, such that leukoplakia 
on the ventro-lateral tongue and floor of mouth were more likely to be DF 
post-laser, were significant influences (p=0.01 and p=0.04, respectively). 
Laser excision surgery was more effective than ablation techniques in 




This paper has attempted a detailed review of the presentation and clinical 
outcome of 198 PMD patients diagnosed as OLL or PVL.  Patients were 
identified from a previously reported cohort, which benefited from uniform 
diagnoses, consistent treatment intervention, long-term surveillance and 
documented clinical outcome3,5,12.  
 
Oral Lichenoid Lesions 
Twenty percent of PMD lesions in this cohort were diagnosed as OLL; this is 
similar to previous reports suggesting that up to 29% of PMD may exhibit 
lichenoid features. Although OLL are classically described as solitary 
erythroleukoplakic lesions, mimicking the appearance of mucosal lichen 
planus, strict definition remains elusive9. Over 80% of OLL in this study 
appeared as leukoplakia, and were particularly common on ventro-lateral 
tongue, floor of mouth and labio-buccal mucosa sites; most were excised by 
laser surgery.  
 
Upon microscopic examination, 72% of OLL in the study exhibited dysplasia 
most frequently mild or moderate in extent. Whilst the diagnostic term 
‘lichenoid dysplasia’ has been proposed, raising specific concerns regarding 





supported in the literature9,13,14.  It remains unclear whether LI drives MT, 
similar to chronic inflammation in the colonic cancer model, or is an immune 
response to atypical oral epithelium1,9; the latter hypothesis is favoured by 
the authors of this paper.  
 
Whilst the prognostic significance of OLL has been debated for many years 
and is still controversial, there is increasing recognition in clinical practice 
that isolated OLL, especially those arising on the tongue, should be 
considered at high risk of MT and treated by interventional surgery5,15. 
Ultimately, OLL patients in this study were less likely to be DF post-treatment 
than those in the overall PMD cohort (69.5% vs 74.2%, respectively). MT 
following laser treatment affected 2 patients (1.7%), which is similar to the 
1.09% to 2.1% range quoted in the literature9,16.  
 
It has not been common practice to continuously follow-up patients with OLL, 
although some authors now recommend this practice in specialist clinics to 
monitor for early cancerous change7,8,15. The findings of this study certainly 
support this approach. 
 
Proliferative Verrucous Leukoplakia 
PVL was diagnosed in 13.6% of the study cohort, much higher than the 
previously quoted prevalence of 0.1% in the UK population17. Lesions were 
predominantly leukoplakic in appearance (97.5%) with a high predilection for 
labio-buccal and gingival / alveolar sites (40%), and exhibiting more 
widespread mucosal involvement than OLL. A higher percentage of PVL 
(85%) showed dysplasia compared with OLL, although the majority were 
diagnosed as mild. Clinical outcomes were very similar to OLL, with DF 
status confirmed in 65% of patients and 2 (2.5%) progressing to OSCC, 
considerably better than previously reported 15% DF and 70% MT rates 
post-PVL treatment and strongly supportive of the efficacy of CO2 laser as a 
treatment modality3,20. 
   
Traditionally, PVL diagnoses were made late during PMD presentation once 





become apparent. Increasingly, specialist pathologists have attempted 
earlier and more objective diagnoses for verrucous hyperplastic lesions 
considered part of the PVL spectrum, probably explaining their increased 
diagnoses during the latter years of this study3,17.  
 
Salient criteria supporting PVL diagnoses have included: patients older than 
60 years, a female: male ratio of 4:1, limited use of tobacco and alcohol, 
multiple-site disease and progressive clinical and histopathological features 
confirmed during follow-up9,17. Although PVL patients in this study were seen 
to be older, they displayed a more equal sex distribution, were active users 
of tobacco and alcohol, and were diagnosed as ‘single-site’ disease. It may 
be that these clinical presentations were at an early phase in PVL disease 
progression.  
 
Diagnostic Discrepancy or Disease Evolution? 
In 10 patients (5%) features of both OLL and PVL were identified, primarily in 
‘same-site’ lesions at different time points. Whether this represents a 
discrepancy between incision and excision biopsy diagnoses, which is known 
to affect nearly 50% of PMD cases3, or is representative of disease evolution 
remains unknown. Histopathologically, PVL is known to exhibit a continuum 
of morphological change, passing through an initial hyperkeratosis phase 
usually without dysplasia, through verrucous hyperplasia leading on to 
verrucous carcinoma and invasive OSCC18. Complicating the early phase of 
PVL are the presence of lymphocytic infiltrates in the immediate sub-
epithelial region similar to OLL9,19,20. It is not an unreasonable hypothesis, 
therefore, that OLL and PVL may be part of the same PMD continuum.  
 
Conclusions 
Patient observational studies improve knowledge of PMD natural history. 
This paper reviewed the diagnosis and management of OLL and PVL. It was 
not a prospective or randomised trial and clinician bias may have influenced 
patient recruitment, treatment intervention and disease progression3; it is 





PMD behaviour or treatment contributes to clinical outcome22,23. Early 
intervention, especially laser excision surgery, is clearly an effective strategy 
with significantly improved DF status for treated patients. Whilst larger, multi-
centre population studies are required, this study has demonstrated a 
continuum of clinico-pathological features for both OLL and PVL affecting 
one-third of PMD patients in North-East England. Whilst the OLL/PVL 
conundrum remains, clinicians specialising in PMD need to remain highly 
vigilant for signs and symptoms suggestive of this important PMD sub-group, 
liaising closely with pathology colleagues in agreeing diagnostic criteria 
appropriately tailored to individual, presenting cases.  
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TABLE 1: CLINICO-PATHOLOGICAL, TREATMENT AND CLINICAL OUTCOME 









1 1996/1 F 42 LK Alveolus HK + LI Excision Further 
2 1998/1 M 60 ELK Buccal Severe Dysplasia + LI Excision Further 
3 1998/2 M 66 LK Buccal Mild Dysplasia + LI Excision DF 
4 1998/3 M 70 LK FOM Severe Dysplasia + LI Excision DF 
5 1991/1 F 42 LK FOM Severe Dysplasia + LI Excision DF 
6 1991/2 F 80 LK Lateral 
Tongue 
Severe Dysplasia + LI Excision DF 
7 1999/3 M 53 LK FOM Moderate Dysplasia + LI Excision Further 
8 2000/1 M 35 LK FOM Moderate Dysplasia + LI Excision DF 
9 2000/2 F 59 LK FOM Moderate Dysplasia + LI Excision DF 
10 2000/3 M 49 LK FOM Moderate Dysplasia + LI Excision DF 
11 2000/4 F 67 LK Buccal Moderate Dysplasia + LI Excision DF 
12 2000/5 F 40 LK FOM Moderate Dysplasia + LI Excision DF 
13 2000/6 F 54 LK Alveolus Moderate Dysplasia + LI Ablation Further 
14 2000/7 M 35 LK FOM Moderate Dysplasia + LI Excision DF 
15 2000/8 M 27 ELK FOM Moderate Dysplasia + LI Excision DF 
16 2000/9 M 65 LK Ventral 
Tongue 
Mild Dysplasia + LI Excision Further 
17 2000/10 M 49 LK Labial 
Comm 
Severe Dysplasia + LI Excision Further 
18 2001/1 M 48 LK FOM Moderate Dysplasia + LI Excision DF 
19 2001/2 F 59 LK Alveolus Moderate Dysplasia + LI Ablation DF 
20 2001/3 F 78 LK Ventral 
Tongue 
Moderate Dysplasia + LI Excision DF 
21 2001/4 M 48 LK FOM Moderate Dysplasia + LI Excision DF 
22 2001/5 M 65 ELK Buccal HK + LI Excision DF 
23 2001/6 M 65 LK Ventral 
Tongue 
Moderate Dysplasia + LI Excision DF 
24 2001/7 M 60 LK FOM Severe Dysplasia + LI Excision Further 
25 2001/8 F 40 LK FOM Moderate Dysplasia + LI Excision DF 
26 2002/1 M 27 LK FOM Moderate Dysplasia + LI Excision Further 
27 2002/2 F 76 LK Buccal Moderate Dysplasia + LI Excision DF 












29 2003/2 F 73 ELK Lateral 
Tongue 
HK + LI Excision Further 
30 2003/3 F 53 ELK Buccal Moderate Dysplasia + LI Ablation Further 
31 2003/4 M 44 ELK Lateral 
Tongue 
Severe Dysplasia + LI Excision Further 
32 2003/5 F 45 LK Lateral 
Tongue 
Mild Dysplasia + LI Ablation DF 
33 2004/1 F 63 LK FOM Moderate Dysplasia + LI Excision DF 
34 2004/2 F 68 LK Lateral 
Tongue 
HK + LI Excision MT 
35 2004/3 M 73 LK Lateral 
Tongue 
Severe Dysplasia + LI Excision DF 
36 2004/4 M 38 LK FOM Mild Dysplasia + LI Excision DF 
37 2004/5 F 44 ELK Labial 
Comm 
Mild Dysplasia + LI Excision DF 
38 2006/1 M 43 LK Lateral 
Tongue 
Mild Dysplasia + LI Excision DF 
39 2006/2 M 84 LK Ventral 
Tongue 
Moderate Dysplasia + LI Excision DF 
40 2006/3 M 40 LK Palate Moderate Dysplasia + LI Excision DF 
41 2006/4 F 50 LK FOM Mild Dysplasia + LI Excision DF 
42 2006/5 M 49 LK Ventral 
Tongue 
Mild Dysplasia + LI Excision DF 
43 2007/1 F 64 ELK Alveolus HK + LI Ablation Further 
44 2008/1 M 70 LK FOM Mild Dysplasia + LI Excision DF 
45 2008/2 M 43 ELK FOM Mild Dysplasia + LI Excision Further 
46 2008/3 F 51 LK Buccal HK + LI Excision DF 
47 2008/4 M 70 LK Lateral 
Tongue 
Mild Dysplasia + LI Excision MT 
48 2008/5 F 69 LK Buccal HK + LIǂ Excision Further 
49 2008/6 F 65 ELK Alveolus HK + LI Ablation DF 
50 2008/7 F 55 LK FOM Mild Dysplasia + LI Excision DF 
51 2009/1 M 56 LK Lateral 
Tongue 
Mild Dysplasia + LI Excision DF 
52 2009/2 M 48 LK Ventral 
Tongue 
Severe Dysplasia + LI Excision Further 
53 2009/3 M 53 LK Lateral 
Tongue 
Moderate Dysplasia + LI Excision DF 
54 2009/4 F 62 LK Ventral 
Tongue 
Moderate Dysplasia + LI Excision DF 
55 2009/5 M 56 LK FOM Mild Dysplasia + LI Excision DF 












57 2010/2 M 67 ELK Lateral 
Tongue 
Mild Dysplasia + LI Excision Further 
58 2010/3 M 58 LK Buccal HK + LI Excision Further 
59 2010/4 F 73 LK Lateral 
Tongue 
HK + LI Excision DF 
60 2010/5 F 50 LK Palate HK + LI Excision DF 
61 2010/6 M 72 LK Alveolus HK + LI* Excision Further 
62 2010/7 F 44 ELK Lateral 
Tongue 
Mild Dysplasia + LI Excision DF 
63 2010/8 F 54 LK Gingiva HK + LI Excision DF 
64 2010/9 M 60 LK Lateral 
Tongue 
Moderate Dysplasia + LI Excision DF 
65 2010/10 F 48 LK Ventral 
Tongue 
Mild Dysplasia + LI Excision DF 
66 2011/1 M 63 LK Labial Severe Dysplasia + LI Ablation Further 
67 2011/2 M 57 LK Palate Moderate Dysplasia + LI Excision Further 
68 2011/3 M 57 LK FOM Severe Dysplasia + LI Excision DF 
69 2011/4 F 77 LK Buccal Mild Dysplasia + LI Excision Further 
70 2011/5 F 72 LK FOM Mild Dysplasia + LI* Excision Further 
71 2011/6 F 74 LK Gingiva HK + LI Ablation DF 
72 2011/7 M 27 LK FOM Mild Dysplasia + LI Excision DF 
73 2011/8 F 78 ELK Buccal HK + LI Excision DF 
74 2011/9 F 49 LK Lateral 
Tongue 
Mild Dysplasia + LI Excision DF 
75 2011/10 M 41 LK FOM Mild Dysplasia + LI Excision DF 
76 2011/11 F 56 ELK Lateral 
Tongue 
Mild Dysplasia + LI Excision Further 
77 2011/12 F 55 LK Lateral 
Tongue 
Mild Dysplasia + LI Excision DF 
78 2011/13 F 65 LK Gingiva HK + LI Ablation DF 
79 2011/14 M 49 ELK Labial 
Comm 
Mild Dysplasia + LI Excision Further 
80 2011/15 F 57 LK Gingiva HK + LI Ablation Further 
81 2012/1 M 62 LK Labial 
Comm 
HK + LI Excision DF 
82 2012/2 M 51 LK Buccal HK + LI Excision Further 
83 2012/3 M 73 LK Lateral 
Tongue 
Mild Dysplasia + LI Excision DF 
84 2012/4 F 24 LK FOM Mild Dysplasia + LI Excision Further 
85 2012/5 M 62 LK Labial 
Comm 
HK + LI Excision DF 












87 2012/7 F 35 LK Labial 
Comm 
Mild Dysplasia + LI Excision DF 
88 2012/8 M 67 LK Lateral 
Tongue 
Mild Dysplasia + LI Excision DF 
89 2012/9 F 52 LK Palate Mild Dysplasia + LI Excision DF 
90 2012/10 F 63 LK Gingiva HK + LI Ablation DF 
91 2013/1 M 70 ELK Buccal Mild Dysplasia + LI Excision Further 
92 2013/2 F 83 LK Buccal HK + LI Excision Further 
93 2013/3 M 52 ELK Buccal HK + LI Excision DF 
94 2013/4 F 41 LK Buccal HK + LI Excision DF 
95 2013/5 M 42 LK FOM Mild Dysplasia + LI Excision DF 
96 2013/6 F 63 LK Alveolus HK + LI Ablation Further 
97 2013/7 F 66 LK Ventral 
Tongue 
Mild Dysplasia + LI Excision DF 
98 2013/8 F 66 LK Dorsum 
Tongue 
Severe Dysplasia + LI Excision DF 
99 2013/9 M 72 LK Buccal Severe Dysplasia + LI Excision DF 
100 2013/10 F 60 LK Alveolus HK + LI Ablation Further 
101 2013/11 M 76 LK Ventral 
Tongue 
Moderate Dysplasia + LI Excision DF 
102 2013/12 F 60 LK Buccal Mild Dysplasia + LI Excision DF 
103 2013/13 F 74 LK Buccal Mild Dysplasia + LI Excision DF 
104 2013/14 F 79 LK Buccal HK + LI Excision DF 
105 2013/15 F 52 LK Lateral 
Tongue 
Severe Dysplasia + LI Excision Further 
106 2013/16 F 64 ELK Buccal HK + LI Excision DF 
107 2013/17 F 60 LK Alveolus HK + LI Excision DF 
108 2013/18 F 66 ELK Lateral 
Tongue 
Moderate Dysplasia + LI Excision DF 
109 2013/19 F 61 LK Alveolus HK + LI Excision DF 
110 2013/20 M 55 LK Lateral 
Tongue 
Mild Dysplasia + LI Excision DF 
111 2013/21 F 50 LK FOM HK + LI Excision DF 
112 2013/22 M 58 LK Lateral 
Tongue 
Severe Dysplasia + LI Excision DF 
113 2013/23 M 59 LK Lateral 
Tongue 
Moderate Dysplasia + LI Excision Further 
114 2014/1 F 43 LK FOM Mild Dysplasia + LI Excision DF 
115 2014/2 M 65 LK Labial 
Comm 
Mild Dysplasia + LI Excision DF 
116 2014/3 M 52 LK Labial 
Comm 












117 2014/4 M 60 LK Buccal Mild Dysplasia + LI Excision DF 
118 2014/5 F 53 LK Lateral 
Tongue 
Severe Dysplasia + LI Excision DF 
 
LK: leukoplakia; ELK: erythroleukoplakia; Labial Comm: Labial Commissure; FOM: floor of 
mouth; HK: hyperkeratosis; LI: lichenoid inflammation; DF: disease free; MT: malignant 




























TABLE 2: CLINICO-PATHOLOGICAL, TREATMENT AND CLINICAL OUTCOME 




No Sex Age Lesion Site 
Histopathology 
Diagnoses Treatment Outcome 
1 2000/1 M 85 LK Lateral 
Tongue 
Moderate Dysplasia PVL Ablation DF 
2 2000/2 M 82 LK Buccal Moderate Dysplasia PVL Excision DF 
3 2002/1 F 61 LK FOM Moderate Dysplasia PVL Excision DF 
4 2006/1 M 63 LK Lateral 
Tongue 
PVL Excision DF 
5 2007/1 F 62 LK Buccal Mild Dysplasia PVL Excision Further 
6 2007/2 F 33 LK Dorsum 
Tongue 
PVL Excision MT 
7 2007/3 F 94 LK Lateral 
Tongue 
Mild Dysplasia PVL Excision DF 
8 2008/1 F 72 LK Labial Moderate Dysplasia PVL Ablation MT 
9 2008/2 F 62 LK FOM 
 
Mild Dysplasia PVL Excision DF 
10 2009/1 F 60 LK Lateral 
Tongue 
Mild Dysplasia PVL Excision DF 
11 2009/2 F 77 LK Fauces Severe Dysplasia PVL Excision DF 
12 2009/3 F 54 LK Lateral 
Tongue 
PVL Excision DF 
13 2010/1 F 77 LK FOM Moderate Dysplasia PVL Excision DF 
14 2010/2 F 85 LK Lateral 
Tongue 
Mild Dysplasia PVL Excision DF 
15 2010/3 M 69 LK FOM Mild Dysplasia PVL* Excision Further 
16 2010/4 M 58 LK Buccal PVL*  Excision Further 
17 2010/5 F 74 LK Buccal Mild Dysplasia PVL Excision DF 
18 2010/6 M 72 LK Alveolus PVL Excision Further 
19 2010/7 F 53 LK Dorsum 
Tongue 
Mild Dysplasia PVL Excision DF 
20 2010/8 F 71 LK FOM Severe Dysplasia PVL Excision DF 
21 2010/9 M 70 LK Buccal Moderate Dysplasia PVL Excision Further 
22 2010/10 M 79 LK Alveolus Mild Dysplasia PVL Excision Further 
23 2010/11 F 36 LK FOM Mild Dysplasia PVL Excision DF 
24 2011/1 F 77 LK Buccal Mild Dysplasia PVLǂ Excision Further 
25 2011/2 F 61 LK Fauces Moderate Dysplasia PVL Excision Further 
26 2011/3 F 70 LK Buccal Moderate Dysplasia PVL Excision Further 
27 2011/4 F 72 LK FOM Mild Dysplasia PVL Excision Further 
28 2011/5 M 83 LK Labial 
Comm 







No Sex Age Lesion Site 
Histopathology 
Diagnoses Treatment Outcome 
29 2011/6 M 57 LK Palate Mild Dysplasia PVL Excision DF 
30 2011/7 M 65 LK Labial 
 
Moderate Dysplasia PVL Excision DF 
31 2011/8 F 64 LK Lateral 
Tongue 
Mild Dysplasia PVL Excision DF 
32 2011/9 M 50 LK Palate Mild Dysplasia PVL Ablation DF 
33 2011/10 M 38 LK Buccal Mild Dysplasia PVL Excision Further 
34 2011/11 M 38 LK Labial Mild Dysplasia PVL Excision DF 
35 2011/12 F 78 LK Ventral 
Tongue 
Severe Dysplasia PVL Excision DF 
36 2011/13 M 67 LK Fauces Moderate Dysplasia PVL Excision DF 
37 2011/14 M 63 LK Buccal Mild Dysplasia PVL Excision DF 
38 2011/15 M 55 LK Labial Mild Dysplasia PVL Excision Further 
39 2011/16 M 74 LK Lateral 
Tongue 
Mild Dysplasia PVL Excision Further 
40 2011/17 M 46 ELK Labial 
Comm 
Severe Dysplasia PVL Excision Further 
 
41 2011/18 F 58 LK Gingiva Mild Dysplasia PVL Ablation Further 
42 2011/19 M 49 ELK Labial 
Comm 
Moderate Dysplasia PVLǂ Excision Further 
43 2012/1 M 62 LK FOM Moderate Dysplasia PVL Excision Further 
44 2012/2 F 60 LK FOM Mild Dysplasia PVL Excision DF 
45 2012/3 M 74 LK Buccal Moderate Dysplasia PVL  Excision DF 
46 2012/4 F 53 LK FOM Mild Dysplasia PVL Excision DF 
47 2012/5 F 60 LK Lateral 
Tongue 
Moderate Dysplasia PVL Excision DF 
48 2012/6 F 57 LK Dorsum 
Tongue 
Mild Dysplasia PVL Excision Further 
         
49 2012/7 M 48 LK FOM Moderate Dysplasia PVL Excision DF 
50 2012/8 M 40 LK Labial 
Comm 
Severe Dysplasia PVL Excision DF 
51 2012/9 F 51 LK Buccal Mild Dysplasia PVL Excision Further 
52 2012/10 M 74 LK Palate Moderate Dysplasia PVL Excision DF 
53 2012/11 M 60 LK Dorsum 
Tongue 
Mild Dysplasia PVL Excision DF 
54 2012/12 M 64 LK Gingiva PVL Excision Further 
55 2012/13 F 71 LK Buccal Mild Dysplasia PVL Ablation Further 
56 2012/14 M 64 LK Palate Mild Dysplasia PVL Excision DF 
         







No Sex Age Lesion Site 
Histopathology 
Diagnoses Treatment Outcome 
58 2012/16 F 73 LK Lateral 
Tongue 
Moderate Dysplasia PVL Excision DF 
59 2013/1 M 43 LK Labial 
Comm 
Mild Dysplasia PVL Excision DF 
60 2013/2 M 36 LK Labial 
Comm 
Mild Dysplasia PVL Excision DF 
61 2013/3 M 56 LK Labial PVL Ablation Further 
62 2013/4 F 63 LK Gingiva PVL Ablation DF 
63 2013/5 M 75 LK Gingiva Mild Dysplasia PVL Ablation Further 
64 2013/6 F 56 LK Lateral 
Tongue 
Mild Dysplasia PVL Excision DF 
65 2013/7 F 64 LK Alveolus PVL Excision DF 
66 2013/8 M 45 LK Ventral 
Tongue 
Mild Dysplasia PVL Excision DF 
67 2013/9 M 65 LK Buccal Mild Dysplasia PVL Excision DF 
68 2013/10 F 71 LK Buccal Mild Dysplasia PVL Excision DF 
69 2013/11 M 68 LK Alveolus PVL Excision Further 
70 2013/12 F 66 LK FOM Mild Dysplasia PVL Excision DF 
71 2013/13 M 37 LK FOM Moderate Dysplasia PVL Excision DF 
72 2013/14 M 64 LK Gingiva PVL Ablation DF 
73 2013/15 M 82 LK Palate Mild Dysplasia PVL Ablation Further 
74 2014/1 F 65 LK Alveolus Mild Dysplasia PVL Excision DF 
75 2014/2 F 53 LK FOM Mild Dysplasia PVL* Excision Further 
76 2014/3 F 64 LK Alveolus Mild Dysplasia PVL Ablation DF 
77 2014/4 F 49 LK Ventral 
Tongue 
Mild Dysplasia PVL Excision DF 
78 2014/5 M 69 LK Ventral 
Tongue 
Mild Dysplasia PVL* Excision DF 
79 2014/6 M 77 LK Buccal Mild Dysplasia PVL* Excision DF 
80 2014/7 M 59 LK FOM Mild Dysplasia PVL Excision DF 
 
LK: leukoplakia; ELK: erythroleukoplakia; Labial Comm: Labial Commissure; FOM: floor of 
mouth; PVL: proliferative verrucous leukoplakia; DF: disease free; MT: malignant 








TABLE 3:  STATISTICAL ANALYSES OF CLINICO-PATHOLOGICAL FEATURES THAT MIGHT 
INFLUENCE CLINICAL OUTCOME   
(Pearson Chi-Square Testing) 
 
 
       𝝌𝟐    p-value 
Ageǂ 0.60 p=0.44 
Sex 1.48 p=0.30 
Lesion Appearance (Leukoplakia vs Others) 6.62 p=0.01* 
Lesion Site 12.11 p=0.04* 
Dysplasia Severity 2.64 p=0.43 
OLL vs PVL  0.44 p=0.55 
Treatment (Excision vs Ablation) 5.06 p=0.04* 
  
*Statistical Significance at α=0.05 
ǂWald chi-square statistic & p-value computed by logistic regression 
